> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Teva Suspends Sales of ‘Burning’ Migraine Patch
- URL: https://www.fdaweb.com/teva-suspends-sales-of-burning-migraine-patch/
- Published: 2016-06-13T12:00:00.000Z
- Updated: 2026-09-14T21:09:20.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135916

Teva Pharmaceuticals has suspended marketing of its battery-powered Zecuity (sumatriptan iontophoretic transdermal system) patch, indicated for treating acute migraines, while FDA and the company investigate reports of serious burns and potential permanent scarring in product users. A recall has also been initiated, according to the company.

Earlier this month, an agency drug [safety notice](http://www.fda.gov/Drugs/DrugSafety/ucm504588.htm?ref=fdaweb.com) said an investigation was underway to determine the cause and extent of these serious side effects. FDA said it would update the public with new information when its review is complete.

In 2013, the agency approved the single-use patch that delivers sumatriptan through the skin, but marketing of the product did not begin until 9/2015\. Since then, there have been a large number of patients who have reported experiencing burns or scars on the skin where the patch was worn, according to FDA. “The reports included descriptions of severe redness, pain, skin discoloration, blistering, and cracked skin,” it said.